| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
BP-1-102 is a potent, orally bioavailable and selective STAT3 inhibitor, which binds Stat3 with an affinity Kd of 504 nM. BP-1-102 inhibits Stat3 DNA-binding activity in vitro, with an IC50 value of 6.8±0.8 μM. It blocks Stat3-phospho-tyrosine peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8.
| ln Vitro |
The affinity KD of BP-1-102 for Stat3 is 504 nM. In vitro, Stat3 DNA-binding activity is inhibited by BP-1-102, with an IC50 value of 6.8±0.8 μM. It specifically suppresses the growth, survival, migration, and invasion of tumor cells dependent on Stat3 and disrupts interactions between Stat3 and phospho-tyrosine peptides, as well as Stat3 activation at 4-6.8 μM. The suppression of aberrantly active Stat3 in tumor cells by BP-1-102 reduces the expression of Krüppel-like factor 8, c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Cyclin D1[1].
|
||
|---|---|---|---|
| ln Vivo |
Mice therapeutically fed BP-1-102, an orally accessible drug targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon carcinogenesis and diminished production of STAT3/NF-kB-activating cytokines in the neoplastic areas[2]. BP -1-102 is orally accessible and that the drug accumulates in tumor tissues at levels adequate to inhibit aberrantly active Stat3 actions and decrease tumor growth[1].
|
||
| Animal Protocol |
|
||
| References |
|
| Molecular Formula |
C29H27F5N2O6S
|
|
|---|---|---|
| Molecular Weight |
626.59
|
|
| Exact Mass |
626.151
|
|
| CAS # |
1334493-07-0
|
|
| Related CAS # |
|
|
| PubChem CID |
53388144
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.5±0.1 g/cm3
|
|
| Boiling Point |
749.2±70.0 °C at 760 mmHg
|
|
| Flash Point |
406.9±35.7 °C
|
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
|
| Index of Refraction |
1.601
|
|
| LogP |
7.77
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
12
|
|
| Rotatable Bond Count |
9
|
|
| Heavy Atom Count |
43
|
|
| Complexity |
1050
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
WNVSFFVDMUSXSX-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C29H27F5N2O6S/c1-35(43(41,42)28-26(33)24(31)23(30)25(32)27(28)34)15-22(38)36(19-11-12-20(29(39)40)21(37)13-19)14-16-7-9-18(10-8-16)17-5-3-2-4-6-17/h7-13,17,37H,2-6,14-15H2,1H3,(H,39,40)
|
|
| Chemical Name |
4-[(4-cyclohexylphenyl)methyl-[2-[methyl-(2,3,4,5,6-pentafluorophenyl)sulfonylamino]acetyl]amino]-2-hydroxybenzoic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5959 mL | 7.9797 mL | 15.9594 mL | |
| 5 mM | 0.3192 mL | 1.5959 mL | 3.1919 mL | |
| 10 mM | 0.1596 mL | 0.7980 mL | 1.5959 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
